Karyopharm Therapeutics's total assets for Q3 2025 were $96.23M, a decrease of -8.24% from the previous quarter. KPTI total liabilities were $365.49M for the fiscal quarter, a 6.31% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.